vtak20260714_8k.htm
--12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 14, 2026
Catheter Precision, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware | 001-38677 | 38-3661826 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1670 Highway 160 West Suite 205 Fort Mill, SC | 29708 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (973) 691-2000
(Former name or former address, if changed since last report)
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, par value $0.0001 per share | VTAK | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 Unregistered Sales of Equity Securities.
Issuance of Series C-3 Convertible Preferred Stock
On July 15, 2026, Catheter Precision, Inc. (the “Company”) consummated the closing (the “Series C-3 Closing”) of its previously disclosed sale and issuance of an aggregate of 3,470 shares of the Company’s newly designated Series C-3 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share (the “Series C-3 Preferred Stock”), for aggregate gross proceeds of $3,470,000. The Series C-3 Preferred Stock was issued pursuant to (i) that certain Securities Purchase Agreement, dated February 6, 2026, by and among the Company and the purchasers signatory thereto, as previously disclosed in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 6, 2026 (the “February 8-K”), and (ii) that certain Securities Purchase Agreement, dated March 9, 2026, by and among the Company and the additional purchasers signatory thereto, as previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2026 (the “March 9 8-K”).
The Series C-3 Closing was subject to the satisfaction of customary closing conditions, including the effectiveness of the Company’s Registration Statement on Form S-1 (File No. 333-296946), which registered the resale of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issuable upon conversion of the Series C-3 Preferred Stock, and which was declared effective by the SEC on July 10, 2026. The required stockholder approval under Section 713 of the NYSE American LLC Company Guide had previously been obtained at a Special Meeting of Stockholders held on April 15, 2026.
The shares of Series C-3 Preferred Stock are convertible, at the option of a holder, into shares of Common Stock at an initial conversion price of $0.632 per share, subject to a floor price of $0.35 per share (which the Company may waive in its sole discretion) and customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar transactions. Conversion is also subject to a beneficial ownership limitation, initially set at 4.99% of the outstanding shares of Common Stock (which may be increased by a holder, on 61 days’ prior written notice to the Company, to a maximum of 9.99%). The other terms of the Series C-3 Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C-3 Convertible Preferred Stock (the “Series C-3 Certificate of Designation”), which was filed by the Company with the Secretary of State of the State of Delaware on July 14, 2026. A copy of the Series C-3 Certificate of Designation is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Placement Agent
Dawson James Securities, Inc. (“Dawson James”) acted as placement agent for the Company in connection with the Series C-3 Closing. The Company paid Dawson James customary placement agent fees and expenses in connection therewith, as previously disclosed in the February 8-K and the March 9 8-K.
Use of Proceeds
The Company intends to use the net proceeds from the Series C-3 Closing for working capital, repayment of loans and general corporate purposes.
Exemption from Registration
The Series C-3 Preferred Stock was issued, and any shares of Common Stock issuable upon conversion thereof will be issued, in transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving any public offering. The Company has concluded that the foregoing exemption is available based on the representations made by the purchasers, including that each purchaser is an “accredited investor” as defined in Rule 501 of Regulation D and acquired the securities for investment only and not with a view to, or for sale in connection with, any distribution thereof. The offerings did not involve any general solicitation or general advertising, and appropriate transfer restrictions and customary restrictive legends have been imposed on the securities.
The information set forth in this Item 3.02 is being provided in supplement to the disclosures previously made by the Company in the February 8-K and the March 9 8-K (collectively, the “Prior 8-Ks”), and is qualified in its entirety by reference to the descriptions of the foregoing transactions and the related transaction documents in the Prior 8-Ks.
Item 3.03 Material Modification to Rights of Security Holders.
The information set forth under Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. The Series C-3 Preferred Stock, upon issuance, ranks senior to the Common Stock with respect to dividends and distributions on liquidation, dissolution or winding-up of the Company, and conversion of the Series C-3 Preferred Stock into Common Stock will result in dilution of the existing holders of Common Stock. The rights, preferences, privileges and restrictions of the Series C-3 Preferred Stock, including with respect to dividends, voting, liquidation, conversion and protective provisions, are as set forth in the Series C-3 Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On July 14, 2026, the Company filed the Series C-3 Certificate of Designation with the Secretary of State of the State of Delaware. The Series C-3 Certificate of Designation designates 3,470 shares of the Company’s authorized preferred stock as Series C-3 Convertible Preferred Stock.
The foregoing description of the Series C-3 Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the full text of the Series C-3 Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description |
3.1 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 15, 2026 | ||
CATHETER PRECISION, INC. | ||
By: | /s/ Philip Anderson | |
Philip Anderson | ||
Chief Financial Officer | ||